ASP1570, ASP1570, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants with Locally Advanced or Metastatic Solid Tumors

This study is testing a new drug, ASP1570, on its own and with other cancer treatments for advanced solid tumours. It aims to see how safe the new drug is and how well it works to shrink tumours or stop them from growing. It's for adults aged 18 and over.